Corporate Radar: Gujarat Themis Biosyn to go ex-dividend; Orchid Pharma board meeting and more

Corporate Radar: Gujarat Themis Biosyn to go ex-dividend; Orchid Pharma board meeting and more
By , ETMarkets.com
Rate Story
Share
Font Size
Save
Comment
Synopsis

The board of Orchid Pharma will consider and approve, amongst other things, raising of funds and issuance of securities via Qualified Institutions Placement basis. The pharma stock is a multibagger and has surged nearly 18 times in the last five years.

Agencies
There are a host of corporate actions and board meetings scheduled for Thursday.

The board of will consider and approve, amongst other things, raising of funds and issuance of securities via Qualified Institutions Placement basis. The pharma stock is a multibagger and has surged nearly 18 times in the last five years.

Share of will trade ex-dividend. The company had announced an interim dividend of Rs 4.40 per share. The record date for the same is December 2.

The board of will consider a proposal for a stock split today.

Cosmo First and have board meetings today to consider shares buyback.

The board meeting of is to be held today at 04:00 pm to consider and approve the terms and conditions of the rights issue including the determination of the price, record date etc. The media stock is a multibagger and has rallied nearly 16 times in the last 5 years.

board meeting is to be held today to consider the fundraising proposal by way of issuance of listed/unlisted, secured/unsecured, and non-convertible debentures on a private placement basis.
Experience Your Economic Times Newspaper, The Digital Way!

Read More News on

(What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)

Download The Economic Times News App to get Daily Market Updates & Live Business News.

...more
Pick the best stocks for yourself
Powered by
Read before you invest. Insights on Jenburkt Pharmaceuticals Ltd.. Explore Now